Abstract Number: 2666 • 2019 ACR/ARP Annual Meeting
Development and Outcome of Aortic Complications During Tocilizumab (TCZ) Treatment of GCA and Histopathologic Evidence of Residual Inflammation
Background/Purpose: GCA may affect the aorta and lead to dissections and aortic aneurysms. TCZ treatment may control aortic inflammation as demonstrated by CRP normalization and…Abstract Number: 2667 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience
Background/Purpose: Tocilizumab (TCZ) has recently been shown to be effective and safe for the treatment of patients with giant cell arteritis (GCA). Here we describe…Abstract Number: 2751 • 2018 ACR/ARHP Annual Meeting
Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial
Background/Purpose: Adding tocilizumab (TCZ) to tapered prednisone treatment for patients (pts) with giant cell arteritis (GCA) leads to improved rates of sustained glucocorticoid-free remission.1 It…Abstract Number: 2752 • 2018 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice
Background/Purpose: Tocilizumab (TCZ) has showed efficacy in randomized clinical trials in Giant cell arteritis (GCA). Data were of selected patients including many GCA of recent…Abstract Number: 2756 • 2018 ACR/ARHP Annual Meeting
A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatmet with Tocilizumab Compared with Giacta Trial
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…Abstract Number: 2757 • 2018 ACR/ARHP Annual Meeting
A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Background/Purpose: Tocilizumab (TCZ), an anti–interleukin-6 receptor (IL-6R) monoclonal antibody, was recently approved for the treatment of patients with giant cell arteritis (GCA) based on results…Abstract Number: 2758 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study
Background/Purpose: The efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, in patients with refractory GCA has been demonstrated. The purpose of this study was…Abstract Number: 816 • 2017 ACR/ARHP Annual Meeting
Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…Abstract Number: 911 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Background/Purpose: The efficacy and safety of tocilizumab (TCZ), an IL-6 receptor-alpha inhibitor, was evaluated in patients with giant cell arteritis (GCA) in GiACTA, a randomized,…Abstract Number: 2104 • 2016 ACR/ARHP Annual Meeting
Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis
Background/Purpose: IL-6 has been considered a biomarker of disease activity in GCA and a potential therapeutic target. However, the functional role of IL-6 in GCA…Abstract Number: 3142 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Enhances Regulatory T-Cell Activation and Proliferation in Giant Cell Arteritis
Background/Purpose : CD4+ T helper (Th) 17 cells, Th1 cells, and regulatory T-cells (Treg) contribute to the pathogenesis of giant cell arteritis (GCA). Interleukin (IL)-6,…Abstract Number: 1685 • 2013 ACR/ARHP Annual Meeting
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…
ACR Meeting Abstracts